EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines

Sami Salmikangas, Iina Lindholm, Nasrin Sultana, Nanna Merikoski, Kirsi Toivanen, Xiaonan Liu, Markku Varjosalo, Tom Böhling, Tiina Vesterinen, Harri Sihto

Molecular & Cellular Proteomics · 2026-10 · 25 (10) · 101663

DOI: 10.1016/j.mcpro.2026.101663 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026-10. Verfasst von Sami Salmikangas und 9 weiteren Autor:innen. Beteiligte Einrichtung: Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address:…. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 3, Peptide Chain Initiation, Translational. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sigrid Jusélius Foundation, Research Council of Finland, Medical Association of Life and Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclic Nucleotide Phosphodiesterases, Type 3Peptide Chain Initiation, TranslationalHumansCell Line, TumorProtein Interaction MapsHeLa CellsProtein Binding

Stichwörter der Autor:innen

interactomicsmolecular gluesphosphodiesterase 3Aschlafen 12translation initiation

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 3PDE3A protein, human

Autor:innen und Institutionen

  • Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: sami.salmikangas@helsinki.fi.
  • Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki,…
  • Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
  • Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; HUS Diagnostic Center, Department of Pathology, University of Helsinki and Helsinki Unive…
  • HUS Diagnostic Center, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Förderung

  • Sigrid Jusélius Foundation
  • Research Council of Finland
  • Medical Association of Life and Health
  • Outpatient Research Foundation
  • Relander Foundation sr
  • Mary and Georg C Ehrnrooth Foundation

Zitieren

APA

Salmikangas, S., Lindholm, I., Sultana, N., Merikoski, N., Toivanen, K., Liu, X., Varjosalo, M., Böhling, T., Vesterinen, T., & Sihto, H. (2026). Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines. Molecular & Cellular Proteomics, 25(10), 101663. https://doi.org/10.1016/j.mcpro.2026.101663

Vancouver

Salmikangas S, Lindholm I, Sultana N, Merikoski N, Toivanen K, Liu X, et al. Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines. Molecular & Cellular Proteomics. 2026;25(10):101663. doi:10.1016/j.mcpro.2026.101663

BibTeX
@article{Salmikangas2026,
  author = {Salmikangas, Sami and Lindholm, Iina and Sultana, Nasrin and Merikoski, Nanna and Toivanen, Kirsi and Liu, Xiaonan and Varjosalo, Markku and Böhling, Tom and Vesterinen, Tiina and Sihto, Harri},
  title = {Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines},
  journal = {Molecular & Cellular Proteomics},
  year = {2026},
  volume = {25},
  number = {10},
  pages = {101663},
  doi = {10.1016/j.mcpro.2026.101663}
}
Kostenlos starten →